Impact of Baseline BMI on Glycemic Control and Weight Change with Metformin Monotherapy in Chinese Type 2 Diabetes Patients: Phase IV Open-Label Trial

Ji, Linong; Li, Hongmei; Guo, Xiaohui; Li, Yan; Hu, Renming; Zhu, Zhengying
February 2013
PLoS ONE;Feb2013, Vol. 8 Issue 2, p1
Academic Journal
Background: Differences exist between treatment recommendations regarding the choice of metformin as first-line therapy for type 2 diabetes patients according to body mass index (BMI). This study compared the efficacy of metformin monotherapy among normal-weight, overweight, and obese patients with newly diagnosed type 2 diabetes. Methods: In this prospective, multicenter, open-label study in China, patients aged 23–77 years were enrolled 1∶1:1 according to baseline BMI: normal-weight (BMI 18.5−23.9 kg/m2; n = 125); overweight (BMI 24.0−27.9 kg/m2; n = 122) or obese (BMI ≥28 kg/m2; n = 124). Extended-release metformin was administered for 16 weeks (500 mg/day, up-titrated weekly to a maximum 2,000 mg/day). The primary efficacy endpoint was the effect of baseline BMI on glycemic control with metformin monotherapy, measured as the change from baseline in glycosylated hemoglobin (HbA1c) at week 16 compared among BMI groups using ANCOVA. Other endpoints included comparisons of metformin’s effects on fasting plasma glucose (FPG), lipid levels and body weight. Results: Mean HbA1c decreases at week 16, adjusted for baseline values, were –1.84%, –1.78% and –1.78% in normal-weight, overweight and obese patients, (P = 0.664); body weight decreased by 2.4%, 3.9% and 3.5%, respectively. FPG levels decreased similarly over time in all BMI groups (P = 0.461) and changes from baseline in high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) did not differ significantly among BMI groups at week 16 (P = 0.143 and 0.451, respectively). Conclusions: Baseline BMI had no impact on glycemic control, weight change or other efficacy measures with metformin monotherapy. These data suggest that normal-weight type 2 diabetes patients would derive the same benefits from first-line treatment with metformin as overweight and obese patients, and are not at increased risk of excess weight loss. Trial Registration: ClinicalTrials.gov NCT00778622


Related Articles

  • Effects of exenatide and metformin in combination on some adipocytokine levels: a comparison with metformin monotherapy. Derosa, Giuseppe; Cicero, Arrigo F.G.; Franzetti, Ivano G.; Querci, Fabrizio; Carbone, Anna; Ciccarelli, Leonardina; D'Angelo, Angela; Fogari, Elena; Maffioli, Pamela // Canadian Journal of Physiology & Pharmacology;Sep2013, Vol. 91 Issue 9, p724 

    The aim of this study was to evaluate the effects of exenatide on levels of serum adipocytokines and on β-cell function. The study was conducted between 2008 and 2012. After a run-in period with metformin, 174 patients with type-2 diabetes were randomly distributed to either a group receiving...

  • Norma TERAPÊUTICA DA DIABETES MELLITUS TIPO 2: METFORMINA Uma Perspectiva Crítica. PINTO, Daniel; HELENO, Bruno; GALLEGO, Rosa; SANTOS, Isabel; SANTIAGO, Luiz Miguel; MARIA, Vasco // Acta Medica Portuguesa;2011, Vol. 24 Issue 2, p331 

    Clinical guidelines have the potential to increase health gains, but also to cause harm. In this opinion article we state some misgivings about the application of the Portuguese National Health Directorate's guideline type 2 diabetes therapy: metformin in primary care. We seek to highlight...

  • Effect of fruit restriction on glycemic control in patients with type 2 diabetes - a randomized trial. Christensen, Allan S.; Viggers, Lone; Hasselström, Kjeld; Gregersen, Søren // Nutrition Journal;2013, Vol. 12, p1 

    Background: Medical nutrition therapy is recognized as an important treatment option in type 2 diabetes. Most guidelines recommend eating a diet with a high intake of fiber-rich food including fruit. This is based on the many positive effects of fruit on human health. However some health...

  • Improvement in insulin sensitivity and β-cell function following ileal interposition with sleeve gastrectomy in type 2 diabetic patients: potential mechanisms. Paula, Aureo; Stival, Alessandro; Halpern, Alfredo; DePaula, Carolina; Mari, Andrea; Muscelli, Elza; Vencio, Sergio; Ferrannini, Ele; De Paula, Aureo Ludovico; Stival, Alessandro R; DePaula, Carolina C L // Journal of Gastrointestinal Surgery;Aug2011, Vol. 15 Issue 8, p1344 

    Introduction: Bariatric surgery in morbidly obese type 2 diabetic (T2DM) patients is associated with high rates of diabetes remission. We investigated the mechanisms of the anti-diabetic effect of the laparoscopic ileal interposition with sleeve gastrectomy (LII-SG) in normal weight...

  • The Effects of Dipeptidyl Peptidase-4 Inhibitors in Treatment of Obese Patients with Type 2 Diabetes. Velija-Asimi, Zelija; Izetbegovic, Sebija; Karamehic, Jasenko; Coric, Jozo; Panjeta, Mirsad; Macic-Dzankovic, Amra; Djelilovic-Vranic, Jasminka; Dizdarevic-Bostandzic, Amela // Medicinski Arhiv;Oct2013, Vol. 67 Issue 5, p365 

    Introduction: Dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of antihyperglycemic drugs that block degradation of incretin hormones. Goal: To assess the effects of treatment with DPP-4 inhibitors on glucoregulation and body weight in obese patients with type 2 diabetes mellitus....

  • Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Kaixin Zhou; Bellenguez, Celine; Spencer, Chris C. A.; Bennett, Amanda J.; Coleman, Ruth L.; Tavendale, Roger; Hawley, Simon A.; Donnelly, Louise A.; Schofield, Chris; Groves, Christopher J.; Burch, Lindsay; Carr, Fiona; Strange, Amy; Freeman, Colin; Blackwell, Jenefer M; Bramon, Elvira; Brown, Mattew; Casas, Juan P.; Corvin, Aiden; Craddock, Nicholas // Nature Genetics;Feb2011, Vol. 43 Issue 2, p117 

    Metformin is the most commonly used pharmacological therapy for type 2 diabetes. We report a genome-wide association study for glycemic response to metformin in 1,024 Scottish individuals with type 2 diabetes with replication in two cohorts including 1,783 Scottish individuals and 1,113...

  • One-Year Treatment With Exenatide Improves β-Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients. Bunck, Mathijs C.; Diamant, Michaela; Cornér, Anja; Eliasson, Bjorn; Malloy, Jaret L.; Shaginian, Rimma M.; Deng, Wei; Kendall, David M.; Taskinen, Marja-Riitta; Smith, Ulf; Yki-Järvinen, Hannele; Heine, Robert J. // Diabetes Care;May2009, Vol. 32 Issue 5, p762 

    OBJECTIVE -- Traditional blood glucose-lowering agents do not sustain adequate glycemic control in most type 2 diabetic patients. Preclinical studies with exenatide have suggested sustained improvements in β-cell function. We investigated the effects of 52 weeks of treatment with exenatide or...

  • Combinación en dosis ijas: una nueva opción terapéutica para la diabetes mellitus tipo 2. Goñi, Karla Martínez; Salazar, Juan Díaz // Medicina Interna de Mexico;sep/oct2012, Vol. 28 Issue 5, p483 

    Diabetes mellitus type 2 is a chronic but controllable degenerative disease. The natural history of its evolution brings like consequence that many patients progress inevitably in spite of the treatment. The main classes of antidiabetics used in monotherapy induces, in the long term, glycemic...

  • Comparative effects of aerobic training and whole body vibration on plasma adiponectin and insulin resistance in type 2 diabetic men. Azarbayjani, Mohammad-Ali; Behboudi, Lale; Aghaalinejad, H.; Salavati, M. // Annals of Biological Research;2011, Vol. 2 Issue 5, p671 

    Background: Aerobic exercise has been identified as a specific and the main strategy in the treatment of patients with type 2 diabetes. However, some of diabetic patients have difficulties doing such exercise. Recently, the use of whole body vibration exercise has been recommended as a passive...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics